|Awarded On||February 16, 2022|
|Title||Turn ON Antitumor Immunity in Metastatic Cancers|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Jinming Gao|
|Cancer Sites||All Sites|
*Pending contract negotiation
Metastatic diseases are responsible for 90% of cancer-related deaths and remain as a paramount challenge in patient care. In recent years, immunotherapy showed promising durable responses in cancer patients. However, generation and sustenance of robust antitumor immunity in metastatic cancers is still a challenging task. In this application, we aim to develop an intravenously injectable nano-immune-therapeutic that turns on innate immune pathways for T cell therapy of metastatic cancers. The technology is based on an ultra-pH sensitive (UPS) nanoparticle platform that was invented as a result of our past CPRIT support. By targeting tumor acidic microenvironment, we successfully imaged a ...